SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: li3511 who wrote (38530)1/9/2017 10:56:44 AM
From: KeeptheFaith3 Recommendations

Recommended By
dorightbythem
drtom1234
Stuart Little

  Read Replies (1) | Respond to of 63307
 
<<<As of this writing, IMMU is down 5.6%, after the company announced earlier this morning a new management plan and—unexpectedly—shares purchased up until January 19 can be voted at the Annual Meeting.

I guess this is the market's verdict on management's alternative.>>>

Yep. I see the market is voting on the latest IMMU Plan for Shareholder Destruction. It seems like every time they open their mouths the stock price goes down.

I am all-in on VB now (as if I wasn't before).

-KTF



To: li3511 who wrote (38530)1/9/2017 1:02:11 PM
From: kdd999  Read Replies (1) | Respond to of 63307
 
What a pathetic offer. Obvious desperation. Seems to me upon cursory reading that this is an admission that they KNOW venbio is going to win. Where did they dig up these people? Is there a list of Bod for hire out there?

On another note, it costs 12m and 8 m up front to get rid of the g's. and we pay yuge royalties to doc forever.

I suppose there is no way to reduce that drain. Even the CFO loser they got last year walks off with $1m in gold.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News